Shire, AbbVie notify CADE of proposed merger

( September 29, 2014, 11:51 GMT | Official Statement) -- MLex Summary: Biopharmaceutical specialists Shire and AbbVie are seeking antitrust clearance for their planned merger to create a new company. For the purpose of the transaction, AbbVie has created a new company, New AbbVie, which will become the holding company of the Shire Group and AbbVie Group. If approved, the companies intend the New AbbVie shares to be traded on the New York Stock Exchange. AbbVie is a research-based biopharmaceutical company listed in New York, while Shire trades its shares in London....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.

Know what others in the room don’t, with features including:

Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Prepare for tomorrow’s regulatory change, today

Related Sections